Drug Profile
Human retinal pigment epithelial cell therapy - Stemedica Cell Technologies
Alternative Names: Stemedyne™ RPELatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Stemedica Cell Technologies
- Class Eye disorder therapies; Neural stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glaucoma; Macular degeneration; Retinitis pigmentosa
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Glaucoma in Russia (Intraocular)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Macular-degeneration in Russia (Intraocular)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Retinitis-pigmentosa in Russia (Intraocular)